The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma.
Saved in:
| Title: | The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma. |
|---|---|
| Authors: | Håkansson, Kjell Erik Julius (AUTHOR), Ibsen, Rikke (AUTHOR), Steen Krogh, Niels (AUTHOR), Baastrup Soendergaard, Marianne (AUTHOR), Hansen, Susanne (AUTHOR), Bjerrum, Anne-Sofie (AUTHOR), von Bülow, Anna (AUTHOR), Hilberg, Ole (AUTHOR), Løkke, Anders (AUTHOR), Bonnesen, Barbara (AUTHOR), Johnsen, Claus Rikard (AUTHOR), Lock-Johansson, Sofie (AUTHOR), Dongo, Lycely (AUTHOR), Bisgaard Borup, Maria (AUTHOR), Vijdea, Roxana (AUTHOR), Makowska Rasmussen, Linda (AUTHOR), Schmid, Johannes Martin (AUTHOR), Ulrik, Charlotte Suppli (AUTHOR), Porsbjerg, Celeste (AUTHOR) |
| Source: | Journal of Asthma. Jul2025, Vol. 62 Issue 7, p1246-1256. 11p. |
| Subjects: | Sick leave, Biotherapy, Disability retirement, Asthmatics, Earned income |
| Abstract: | Introduction: Severe asthma impacts work capacity, but little is known about the effects of biologic therapy on patients' ability to work. We aimed to assess the impact of biologic therapy for severe asthma on work capacity and workforce attachment. Methods: This cohort study used the Danish Severe Asthma Register, comprising all Danish patients with severe asthma initiating biologic therapy. Earned income, hours worked, and workforce attachment were tracked in national databases from one year prior to biologic therapy as well as during 2 years of biologic therapy. Outcomes were compared to age-, sex-, cohabitation- and residence-matched controls from the general population. Results: Overall, 381 patients aged 20–62 years (52% females) were included. Annual weeks worked were lower among patients with severe asthma (adjusted incidence rate ratio (aIRR) 0.82 (0.80–0.84)), driven by increases in sick leave (aIRR 2.77 (2.58–2.98)), unemployment (aIRR 1.38 (1.30–1.46)) and disability pension (aIRR 1.85 (1.76–1.94)). After initiating biologic therapy, patients saw modest increases in annual hours worked during the second year of treatment (aIRR 1.03 (1.03–1.04)). However, patients remained at risk for temporary (OR 1.83 (1.15–2.93)) and permanent (OR 2.67 (1.16–6.16)) workforce withdrawal. Patients achieving on-treatment remission worked significantly more hours compared to non- and clinical responders and had lower unemployment-, sick-leave and disability pension rates both at baseline and after two years. Conclusion: Biologic therapy resulted in a modest increase in hours worked, yet patients remain at significant risk of early workforce withdrawal. Patients achieving remission had a stronger attachment to the workforce, also prior to biologic therapy. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Asthma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
